99Z Stock Overview
A biotechnology company, develops a treatment for sepsis and septic shock in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Modus Therapeutics Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.077 |
| 52 Week High | kr0.23 |
| 52 Week Low | kr0.073 |
| Beta | 0.34 |
| 1 Month Change | 2.12% |
| 3 Month Change | -41.29% |
| 1 Year Change | -63.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 99Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.5% | 0.5% | -0.3% |
| 1Y | -63.8% | -25.8% | 4.5% |
Return vs Industry: 99Z underperformed the German Biotechs industry which returned -25.8% over the past year.
Return vs Market: 99Z underperformed the German Market which returned 4.5% over the past year.
Price Volatility
| 99Z volatility | |
|---|---|
| 99Z Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 99Z's share price has been volatile over the past 3 months.
Volatility Over Time: 99Z's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 2 | John Öhd | www.modustx.com |
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide to treat patients with sepsis, septic shock, and severe malaria conditions, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Modus Therapeutics Holding AB (publ) Fundamentals Summary
| 99Z fundamental statistics | |
|---|---|
| Market cap | €3.26m |
| Earnings (TTM) | -€1.29m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs 99Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 99Z income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr14.96m |
| Earnings | -kr14.96m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 99Z perform over the long term?
See historical performance and comparison